|
|
|
| Evaluation of sensitivity and curative effect of five colorectal cancer
chemotherapy drugs on colorectal cancer cells in Uygur patients |
| Abuduxukuer Mijiti, Zulibiya Simayi, Atikan Kawuli, WANG Lei, SANG Jiang-yong |
| (Cancer Center, the Second People′s Hospital of Kashgar Region, Kashi Xinjiang 844000, China)
|
|
|
|
|
Abstract Objective: To evaluate the sensitivity and efficacy of 5fluorouracil, gemcitabine, cisplatin, oxaliplatin and irinotecan colorectal cancer chemotherapy drugs for colorectal cancer cells in Uygur patients. Methods: Tissue samples from Uighur patients with colorectal cancer were tested for susceptibility by MTT assay. Inverted fluorescence microscopy was used to observe the effect of chemotherapeutic drugs on the morphology of colorectal cancer cells. A total of 60 patients with colorectal cancer were randomly divided into 5Fu group(5fluorouracil+leucovorin), FOLFOX group(5fluorouracil+leucovorin+oxaliplatin),FOLFIRI group(5fluorouracil+leucovorin+irinotecan), 20 patients in each group; after the end of the treatment course, the pelvic cavity was examined by MRI to obtain the tumor signal(ADC value) on the MRI diffusionweighted imaging(DWI) image and the level of tumor markers carcinoembryonic antigen(CEA) and CA199 in serum was detected by a fully automatic electrochemical immunoassay system. Results: The inhibition rates of 5fluorouracil, oxaliplatin and irinotecan on Uygur colorectal cancer cells were significantly higher than that of gemcitabine and cisplatin(P0.05), while both of them in FOLFOX group and FOLFIRI group were significantly lower than in the 5Fu group(P<0.05). Conclusion: 5Fluorouracil, oxaliplatin and irinotecan are highly sensitive to Uigur colorectal cancer patients. The FOLFOX regimen and FOLFIRI regimen with oxaliplatin or irinotecan could effectively improve the prognosis of patients.
|
|
|
|
|
|
| ［1］刘慧敏, 李秀娟, 王磊, 等. 维吾尔族和汉族直肠癌临床病理特征及预后分析\[J\]. 重庆医学, 2015, 44(4): 478-481.［2］李刚,杨润祥,鲍明亮,等. 结直肠癌化疗药物演进及新进展\[J\]. 肿瘤基础与临床, 2015, 28(5): 457-461.［3］王云成,赵娜,杨光. 磁共振弥散加权成像表观扩散系数与直肠癌分化程度的关系\[J\].中国继续医学教育,2018,10(22):58-60.［4］刘存伟. 伊立替康与奥沙利铂、氟尿嘧啶类药物一线治疗晚期结直肠癌的临床研究\[J\]. 北方药学, 2017, 14(3): 34-35.［5］Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱand Ⅲ colon cancer: NSABP C07\[J\]. J Clin Oncol, 2007, 25(16):2205-2211.［6］Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study\[J\]. J Clin Oncol, 2004, 22(2):229-237.［7］国家卫生和计划生育委员会《中国结直肠癌诊疗规范（2017年版》专家组.中国结直肠癌诊疗规范(2017年版)\[J\].中华临床医师杂志(电子版),2018,12(1):3-23.［8］韩建秀,蔺鸿儒.榆林市126例结直肠癌MRDWI与临床病理特征的相关性分析\[J\].解放军预防医学杂志,2018,36(9):1188-1190.［9］李士军, 谭庆丰, 陈洪流, 等. 血清肿瘤标志物CEA、CA199对结直肠癌的诊断价值\[J\]. 肿瘤基础与临床, 2010, 23(4): 298-300.［10］Colucci G, Gebbia V, Paoletti G, et al. Phase Ⅲ randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell′ Italia Meridionale\[J\]. J Clin Oncol, 2005,23(22): 4866-4875. |
|
|
|
2019, Vol. 29 
